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Abstract 
Background: Recent studies proposed GLUT12 to be a major glucose transporter involved in the 
glycolytic metabolism of cancer cells. 
Methods: GLUT12 expression was determined by immunohistochemistry in a selection of cancer 
cell lines and a tumour spheroid model. 
Results: GLUT12 expression was high in A549 and RH-36; low in HT29; and absent in NB-EB 
cancer cell lines. GLUT12 expression was located in the necrotic centre of HT29 spheroids, which 
is characterised by anaerobic metabolism. 
Conclusion: The data supports the involvement of GLUT12 in the glycolytic metabolism of cancer 
cells and therefore, its potential as a novel therapeutic target for cancer treatment. 
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Introduction 
Cancer cells are characterised by uncontrolled 
proliferation and accelerated cellular metabolism. As 
a consequence, these cells have a high ATP demand 
that is satisfied by increased glucose uptake. In addi-
tion, a state where cancer cells inherently favour aer-
obic glycolysis rather than aerobic respiration has 
been widely described [1]. This results in an increased 
demand for ATP because in glycolysis, ATP produc-
tion from glucose is considerably lower than that 
produced during oxidative phosphorylation in aero-
bic respiration. The first rate-limiting step for ATP 
production through glucose metabolism is the 
transport of glucose across the plasma membrane of 
the cell via the facilitative sugar transporters (GLUTs).  
The GLUT/SLC2A family of transporters is 
comprised by 14 isoforms, which are divided into 3 
different classes according to their sequence homol-
ogy [2]. The diverse GLUT isoforms are distributed 
within the body according to their distinct functional 
properties to allow the appropriate distribution of the 
whole-body glucose [2]. Due to high glucose demand, 
most cancer cells overexpress one or more of the 
GLUTs. These GLUTs may or may not be present in 
the respective tissue of origin under non-cancer con-
ditions. Altered expression of GLUTs 1-5 has been 
reported in many tumours such as hepatic (GLUT1, 
-2, -5) [3-5], pancreatic (GLUT1) [3], breast (GLUT1, -2, 
-4) [3-5], lung (GLUT5) [4], digestive (GLUT2, -4, 
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-5) [4, 6, 7], reproductive tract (GLUT5) [4] and lym-
phomas (GLUT5) [5]. GLUT1 expression, in particu-
lar, has been shown to have a close relationship with 
tumour development and with unfavourable progno-
sis [4, 7]. GLUT1 and GLUT3 are also known to be up 
regulated in tumours and normal tissues by hypoxia 
[4, 8, 9].  
GLUT12 belongs to the Class III of GLUT trans-
porters family. It was cloned from the human breast 
adenocarcinoma cell line MCF-7 by its homology with 
GLUT4 [10]. GLUT12 transports 2-deoxy-glucose 
glucose, fructose and galactose, and it has been pro-
posed that could work as a proton coupled symporter 
[10]. GLUT12 protein is expressed in adipose tissue 
and skeletal muscle, where seems to work as an insu-
lin sensitive transporter, and it is also found in small 
intestine and placenta [10]. In tumour tissues, 
GLUT12 has been found in human breast tumours 
[10], human prostate carcinoma and the prostate ad-
enocarcinoma cell line LNCaP [10], oligodendrogli-
omas, oligoastrocytomas and astrocytomas [11]. In-
terestingly, a recent study has shown that p53 tran-
scription factor, a tumour glycolytic metabolism in-
hibitor, specifically represses GLUT12 and GLUT1 
expression, suggesting that both transporters could be 
the main glucose transporters involved in the glyco-
lytic metabolism characteristic of human cancer [12].  
The aim of this study was twofold. Firstly, to 
determine the expression of GLUT12 in a range of 
tumour cell lines in which expression in the corre-
sponding non-malignant tissue has not been reported. 
Secondly, to investigate whether GLUT12 expression 
might, like GLUT1, be induced under hypoxic condi-
tions. 
Materials and methods 
Cell culture 
Human lung adenocarcinoma (A549), colorectal 
adenocarcinoma (HT29), paediatric rhabdomyosar-
coma (RH-36), neuroblastoma (NB-EB) and breast 
adenocarcinoma (MCF-7) cell lines were cultured in 
RPMI 1640 medium supplemented with 10% foetal 
bovine serum (FBS).  
Spheroid cell culture  
HT29 cells were seeded into T75 flasks, previ-
ously coated with agarose gel (0.5% w/v). Cells were 
then cultured under normoxic conditions for ap-
proximately 10 days until cell spheroids were be-
coming visible to the naked eye. Spheroids of ap-
proximately equal sizes were selected and cultured on 
for a further 10 days in a magnetic spinner flask in 
RPMI-1640 (HEPES modification) supplemented with 
10% FBS until fully formed. 
Immunohistochemistry 
Cell monolayers were harvested with tryp-
sin/EDTA solution followed by centrifugation (2000g, 
4oC, 10 minutes). Cell pellets were washed with 
phosphate buffered saline (PBS) before fixation over-
night in 4% formalin buffered saline (4oC). The sphe-
roids were washed in PBS and also fixed overnight. 
After fixation, the cells and spheroids were processed 
through to wax and sectioned (5µM) then mounted 
onto glass slides. For immunohistochemical detection 
of GLUT-12, sections were de-waxed and rehydrated. 
Endogenous peroxidase activity was inhibited with 
3% H2O2 in Tris-buffered saline (TBS) (20 minutes) 
before antigen retrieval was carried out (10mM citric 
acid, 0.5% Tween-20 in TBS (TBS-T) (pH6.0) at 100oC 
for 20 minutes). Sections were blocked with 5% bo-
vine serum albumin (BSA) in TBS-T (20 minutes). 
Sections were then incubated in rabbit anti-GLUT12 
polyclonal antibody (1:200), (bs-2540R, Bioss, Wo-
burn, MA, USA) [13] or GLUT1 (1:100) (GT12-A, ADI, 
San Antonio, TX, USA) overnight at 4ºC or incubated 
in TBS-T as a negative control. Sections were then 
washed in TBS-T before 2oAb treatment (anti-rabbit 
IgG-HRP (Dako, Carpinteria, USA) room temperature 
for 1 hour). The sections were again washed then pe-
roxidase activity was detected using 
3´-3´-diaminobenzidine tetrahydrochloride before 
counter-staining with Haematoxylin. 
Results and Discussion  
In non-malignant tissue, GLUT12 protein is de-
tectable under normal physiological conditions in 
human skeletal muscle, adipose tissue and small in-
testine, but not in brain, liver or kidney. GLUT12 
mRNA has been found in the myocardium, skeletal 
muscle and prostate, and at low levels in the brain and 
kidney, but GLUT12 mRNA has not been detected in 
the lung or colon [14]. Rogers et al (2002) also reported 
breast cancer cell line MCF-7 to be positive for 
GLUT12. Our work confirms this and the specificity of 
the antibody by the intense GLUT12 cytoplasmic and 
nuclear staining in the MCF-7 cell pellet sections 
(Figure 1).  
Interestingly, expression of GLUT12 mRNA was 
detected in different subtypes of human renal tu-
mours [15], human colon carcinoma (HCT116), oste-
osarcoma (U20S and Saos-2) and non-small cell lung 
carcinoma (H1299) cell lines [12]. Based on these data, 
we decided to investigate GLUT12 expression in a 
range of human cancer cell lines derived from tissues 
that have not been reported to express GLUT12 pro-
tein in their non-malignant state. Figure 1 shows that 
GLUT12 was highly expressed in the lung adenocar-
cinoma (A549) and paediatric rhabdomyosarcoma 
(RH-36) cell lines, whereas its expression was rela-
 Journal of Cancer 2015, Vol. 6 
 
http://www.jcancer.org 
141 
tively low in the colorectal adenocarcinoma (HT29) 
cell line and undetectable in the neuroblastoma 
(NB-EB) cell line. Altered protein expression has been 
widely observed in tumours and this has been 
demonstrated with other members of the GLUT fam-
ily. For example, GLUT3 protein is expressed in lung, 
ovarian, and gastric cancers but not in the corre-
sponding normal tissues [16]. Similarly, GLUT5 ex-
pression has been reported in human breast cancer 
cells, but not in normal breast tissue [17]. GLUT12 is 
widely expressed in rat foetus, human placenta and in 
foetal human term membrane [18-20], and foetal tis-
sue, like tumour tissue, has high glucose require-
ments. The fact that GLUT12 is found in foetal tissues 
and in some cancer cell lines, but not in the corre-
sponding normal tissues, suggests a specific role for 
GLUT12 in response to particular metabolic needs. 
This supports the proposal by Zawacka-Pankau et al. 
(2011) that GLUT12 is a major glucose transporter 
involved in glycolytic metabolism of cancer cells. We 
did not detect GLUT12 expression in the neuroblas-
toma (NB-EB) cell line, indicating that GLUT12 may 
not necessarily be expressed in all cancer cell lines or 
tumours. Since GLUT12 expression has been related 
to foetal tissues and the NB-EB cell line is derived 
from embryological cancer, GLUT12 expression could 
have been down regulated during tumour genesis. 
However, further work is necessary to address this 
question.  
 
 
Figure 1. Immunohistochemical detection of GLUT12 in MCF-7 (a-d), NB-EB (e-h), A549 (i-l), RH-36 (m-p), HT29 (q-t) cancer cell lines. 
Sections were incubated with rabbit anti-GLUT12 polyclonal antibody at 1:200 dilution (right panel of each column) or 0.5% Tween-20-TBS (left panel of 
each column). Representative field showing GLUT12-positive staining or negative control staining are shown at magnifications 50X (left column) and 100X 
(right column).  
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Figure 2. A) Immunohistochemichal detection of GLUT12 in 
HT-29 spheroid cell culture. Sections were incubated with rabbit 
anti-GLUT12 polyclonal antibody dilution 1:200. Representative field 
showing GLUT12 staining pattern is shown at magnifications 10X (a), 50X 
(b) and 100X (c). B) Immunohistochemichal detection of GLUT1 
in HT-29 spheroid cell culture. Sections were incubated with rabbit 
anti-GLUT1 polyclonal antibody at 1:100 dilution. Representative field 
showing GLUT1 staining pattern is shown at magnifications 10X. 
HT29 cells have the capacity to form spheroids 
when grown under certain conditions. Cell spheroids 
are spherically symmetric aggregates of cells, which 
have been widely used as in vitro model for the study 
of tumour response to therapy [21]. In the peripheral 
layers of the spheroid, cells are proliferating; deeper 
cells are quiescent and characterised by hypoxia, low 
glucose and ATP production, lactate accumulation, 
and induction of cellular apoptosis/necrosis [22]. 
According to our results, low expression of GLUT12 
was found in HT29 cell monolayers (Figure 1, q-t) and 
high expression in the hypoxic centre of the HT29 
spheroids (Figure 2A). Interestingly, we also found 
that GLUT1 showed a similar pattern of expression in 
HT29 spheroids (Figure 2B). It might be hypothesised 
that increased GLUT12 expression, like GLUT1, is 
involved in cancer cell glycolysis and inducible by 
hypoxia.  
The p53 transcription factor, a tumour glycolytic 
metabolism inhibitor, specifically represses GLUT12 
and GLUT1 expression [12]. Further, p53 expression 
has been found to be low in MCF-7, A549 [23] and 
RH-36 cell lines [24], but high in neuroblastoma and 
HT-29 cell lines [23, 25]. Our results offer further evi-
dence that in cell lines with low levels of p53, there 
would be a correlation with high expression levels of 
GLUT12 and vice versa. This observation excepts 
HT-29 cells, which we found to express GLUT12 de-
spite reports of high levels of p53. However, this cell 
line, in contrast to the other cell lines analysed, ex-
presses mutant p53, which will be inactive and abol-
ish any suppressive effect on GLUT-12 expression 
[23].  
In summary, GLUT12 expression in certain tis-
sues seems to be related to cancer development and 
hypoxia as well as to the characteristic glycolytic me-
tabolism observed in malignant cells. This effect may 
be mediated via a p53-dependent mechanism, where 
down-regulation of GLUT-12 could be an important 
tumour suppressor. This warrants further studies to 
validate GLUT12 as a therapeutic target for novel an-
ticancer treatment. 
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